Benchling Biotech Operating System
The $210M/year GitHub of biotech
Benchling wins if biology starts to look less like isolated lab work and more like repeatable industrial production. The product already covers the core loop of designing DNA or proteins, recording experiments, registering samples, tracking lineage, and managing workflows, which makes it useful not just for one scientist’s notebook but as the system a company uses to run whole programs across drug discovery, cell therapy, agriculture, and other engineered biology work.
-
The product stack is built for this expansion. Notebook captures protocols and results, Molecular Biology handles sequence design and CRISPR guide design, Registry tracks every construct and sample, and Workflows coordinates tasks. That is the software layer needed when many teams are editing, testing, and handing off biological assets at scale.
-
The commercial pattern is also infrastructure like. Benchling had about 1,200 customers and an estimated $210M ARR by May 2024, and it often starts with individual scientists or academics before expanding into large R&D and IT led rollouts. Moderna’s broader deployment shows how a point tool can become a company wide operating system for research.
-
The real market expansion comes from biology moving beyond pharma. Benchling’s own research ties its opportunity to CRISPR, gene therapy, cell therapy, biomaterials, agriculture, and food, where teams still need the same basic system of record, design system, and sample graph even when the end product is a vaccine, a crop trait, or a new material.
From here, the company’s growth is likely to come from going deeper into enterprise workflows and wider across biology powered industries. As more labs standardize data models and connect experiment records to AI analysis and automation, the vendor that already sits at the center of design, sample history, and workflow execution becomes the default infrastructure layer.